June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Macular pigment optical density response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
Author Affiliations & Notes
  • Katherine Meagher
    Chemical and Life Sciences, Macular Pigment Research Group, Waterford, Ireland
  • David Thurnham
    Northern Ireland Centre for Food and Health (NICHE), University of Ulster, Coleraine, United Kingdom
  • Stephen Beatty
    Chemical and Life Sciences, Macular Pigment Research Group, Waterford, Ireland
  • Alan Howard
    Howard Foundation, Cambridge University, Cambridge, United Kingdom
  • Eithne Connolly
    Chemical and Life Sciences, Macular Pigment Research Group, Waterford, Ireland
  • John Nolan
    Chemical and Life Sciences, Macular Pigment Research Group, Waterford, Ireland
  • Footnotes
    Commercial Relationships Katherine Meagher, None; David Thurnham, Howard Foundation, Cambridge UK (C); Stephen Beatty, None; Alan Howard, None; Eithne Connolly, None; John Nolan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3771. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katherine Meagher, David Thurnham, Stephen Beatty, Alan Howard, Eithne Connolly, John Nolan, Macular Pigment Research Group; Macular pigment optical density response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3771.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Research has been ongoing into the role of macular pigment (MP) for vision and age-related macular degeneration (AMD). MP is comprised of the dietary carotenoids lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ). MZ may be important given its predominance over L and Z at the central fovea, due to its strong antioxidant properties, and its capacity to filter short wavelength (blue) light, but few studies have investigated MP response to MZ supplements. This study reports on MP optical density (MPOD) response to three different MP supplements (two containing MZ) in normal subjects (n 36) and in subjects with AMD (n 28).

Methods: Subjects were randomly assigned to: Group 1 (20 mg L, 2 mg Z), Group 2 (10 mg L, 2 mg Z, 10 mg MZ) or Group 3 (3 mg L, 2 mg Z, 17 mg MZ). MPOD was measured at central and peripheral eccentricities (0.25, 0.5, 1.0 and 1.75) using customised heterochromatic flicker photometry. MPOD was assessed at baseline and every two weeks over an eight week study period.

Results: The MPOD response of AMD subjects was comparable to that of normal subjects, with the exception of Group 2, where AMD subjects demonstrated a greater MPOD response (AMD: 0.179 ± 0.075; Normal: 0.137 ± 0.070; P=0.024) at an eccentricity of 1.75. MPOD at 0.25 eccentricity increased significantly in Group 1 (0.095±0.066 [22%]; P<0.001) and Group 2 (0.147±0.078 [34%]; P<0.001), and in Group 3 (0.0906±0.100 [19%]; P=0.003). MPOD at 0.5 eccentricity increased significantly in Group 1 (0.103±0.076 [30%]; P<0.001), Group 2 (0.129±0.076 [37%]; P<0.001), and in Group 3 (0.088±0.095 [23%]; P=0.002). MPOD at 1.0 eccentricity increased significantly in Group 1 (0.079±0.065 [35%]; P<0.001), Group 2 (0.072±0.051 [31%]; P<0.001), and in Group 3 (0.052±0.066 [19%]; P<0.007). MPOD at 1.75 eccentricity increased significantly in Group 1 (0.056±0.055 [44%]; P<0.001) and Group 2 (0.057±0.044 [55%]; P<0.001), but not in Group 3 (0.019±0.062 [12%]; P=0.242).

Conclusions: The formulation containing all three macular carotenoids (Group 2) was most efficacious in terms of enriching MPOD across all measured eccentricities. Of interest, Group 3 (the high MZ group) enriched central MPOD, but not peripheral MPOD. This data is consistent with recent publications demonstrating a beneficial effect of including MZ in a supplement, particularly for increasing central MPOD.

Keywords: 412 age-related macular degeneration • 444 carotenoids/carotenoid binding proteins • 587 macular pigment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×